WO2017011973A1 - Utilisation de composé de statine pour le traitement de cancers de l'estomac - Google Patents

Utilisation de composé de statine pour le traitement de cancers de l'estomac Download PDF

Info

Publication number
WO2017011973A1
WO2017011973A1 PCT/CN2015/084434 CN2015084434W WO2017011973A1 WO 2017011973 A1 WO2017011973 A1 WO 2017011973A1 CN 2015084434 W CN2015084434 W CN 2015084434W WO 2017011973 A1 WO2017011973 A1 WO 2017011973A1
Authority
WO
WIPO (PCT)
Prior art keywords
gastric cancer
cancer cells
group
results
treated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2015/084434
Other languages
English (en)
Chinese (zh)
Inventor
吴俊颖
陈筱萍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taichung Veterans General Hospital
Original Assignee
Taichung Veterans General Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taichung Veterans General Hospital filed Critical Taichung Veterans General Hospital
Priority to PCT/CN2015/084434 priority Critical patent/WO2017011973A1/fr
Publication of WO2017011973A1 publication Critical patent/WO2017011973A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones

Definitions

  • the invention relates to a second use of a compound, in particular to the use of a statin for the treatment of gastric cancer.
  • gastric cancer is the fifth leading cause of cancer death.
  • Gastric cancer is characterized by mucosal lesions in the stomach, which produce ulcers, which in turn cause malignant tumor cells to form in the stomach.
  • the cells in the stomach will not naturally undergo apoptosis, and will continue to undergo cell division and proliferation, and the gastric cancer cells will simultaneously invade the growth range of normal cells during the process of proliferation, and then gradually invade the stomach and other organs, causing the cancer cells to migrate. Since the majority of gastric cancer patients have a distal part of the stomach, and gastric cancer patients have no specific clinical symptoms, most patients with gastric cancer are diagnosed with advanced gastric cancer. Therefore, the mortality rate of gastric cancer has not been reduced. .
  • the clinical treatment of gastric cancer includes surgical resection, chemotherapy, radiation therapy, and targeted drugs.
  • the most important treatment is surgery, even for patients who cannot be cured by surgery, they will still be palliative. Excision to slow tumor growth and prevent tumor metastasis.
  • Chemotherapy achieves the goal of killing or controlling cancer cells by administering appropriate anticancer agents to patients.
  • Current research indicates that chemotherapy is not effective for gastric cancer, and the efficacy of treatment with a single drug is only 20 %, even with multiple drugs, the expected therapeutic effect is not achieved.
  • Radiation therapy causes X-rays or particles to kill cancer cells.
  • radiation therapy is an adjuvant therapy, which is used to remove cancer cells that cannot be removed, residual or invisible to the naked eye, and can only achieve local control of cancer cells.
  • Targeted drugs are the focus of current treatments for gastric cancer. The current study found that for patients with gastric cancer specimens with HER-2 positive staining, the efficacy of HER-2 target drugs is better than traditional chemotherapy, but the target drugs cannot. Adapting to all patients with gastric cancer, and the high cost of medical care, many cancer patients can not afford the drug and miss treatment.
  • the main object of the present invention is to provide a use of a statin compound for the manufacture of a pharmaceutical composition for treating gastric cancer, which can be used clinically effectively and safely.
  • Another object of the present invention is to provide a use of a statin compound for reducing the development of a drug. Ben, and save time in drug development.
  • the present invention selects a statin having an activity for treating gastric cancer from an existing drug, and can effectively improve or treat gastric cancer by administering an effective amount of a statin compound to an individual suffering from gastric cancer.
  • a use of a statin for the manufacture of a pharmaceutical composition for treating gastric cancer is disclosed, wherein the statin compound can effectively inhibit gastric cancer cell growth, migration and invasion, and induce gastric cancer cells.
  • the pharmaceutical composition containing the statin compound disclosed in the present invention does have an effect of treating gastric cancer.
  • the statin is lovastatin, simvastatin, fluvastatin, atorvastatin, pravastatin, rosuvastatin Rosuvastatin or pitavastatin.
  • Figure 1 shows the cell viability of AGS, MKN45 and TSGH9201 gastric cancer cell lines treated with different concentrations of statins.
  • Figure 2A shows the cellular activity of AGS gastric cancer cell lines treated with statins at different times.
  • Figure 2B shows the cell viability of MKN45 gastric cancer cell lines treated with statins at different times.
  • Figure 2C shows the cellular activity of the TSGH9201 gastric cancer cell line treated with statins at different times.
  • Figure 3A shows the results of flow cytometry analysis of AGS gastric cancer cell lines after treatment with different concentrations of statins.
  • Figure 3B shows the results of measuring the number of cells in a MKN45 gastric cancer cell line treated with different concentrations of statins by flow cytometry.
  • Figure 3C shows the results of measuring the number of cells in a TSGH9201 gastric cancer cell line treated with different concentrations of statins by flow cytometry.
  • Figure 4A shows the results of TUNEL detection of apoptosis in AGS gastric cancer cell lines treated with different concentrations of statins.
  • Figure 4B shows the results of TUNEL detection of apoptosis in MKN45 gastric cancer cell lines treated with different concentrations of statins.
  • Figure 4C shows the results of TUNEL detection of apoptosis in TSGH9201 gastric cancer cell lines treated with different concentrations of statins.
  • Fig. 5 shows the expression of AGS, MKN45 and TSGH9201 gastric cancer cells treated with statins at different times by Western blotting, and the expression of proteins regulating gastric cancer cell apoptosis in each gastric cancer cell was detected.
  • Figure 6A shows the different treatments of each group of AGS gastric cancer cells cultured in transwell medium for 12 hours. The results of cell transfer of AGS gastric cancer cells in each group were observed and analyzed.
  • Fig. 6B shows the results of cell migration of each group of MKN45 gastric cancer cells after different treatments of each group of MKN45 gastric cancer cells cultured in transwell medium for 12 hours.
  • Fig. 6C shows the results of cell transfer of each group of TSGH9201 gastric cancer cells after differently treated groups of TSGH9201 gastric cancer cells cultured in transwell medium for 12 hours.
  • Fig. 7A shows the results of cell transfer of each group of AGS gastric cancer cells after 16 hours of culture in a colloidal medium by different treatments of each group of AGS gastric cancer cells.
  • Fig. 7B is a result of analyzing the cell transfer of each group of MKN45 gastric cancer cells after being cultured for 16 hours in colloidal medium by differently treated groups of MKN45 gastric cancer cells.
  • Fig. 7C is a result of analyzing the cell transfer of each group of TSGH9201 gastric cancer cells after being cultured for 12 hours in colloidal medium by differently treated groups of TSGH9201 gastric cancer cells.
  • Fig. 8A shows the results of fluorescent staining of gastric cancer cells of different groups of AGS treated with different treatments, and the results of fluorescence staining of gastric cancer cells of each group were observed by confocal microscopy.
  • FIG. 8B shows the results of fluorescent staining of each group of MKN45 gastric cancer cells treated with different treatments, and the results of fluorescence staining of each group of MKN45 gastric cancer cells were observed by confocal microscopy.
  • 8C shows the results of fluorescent staining of gastric cancer cells of different groups of TSGH9201 treated with different treatment, and the results of fluorescence staining of gastric cancer cells of each group were observed by confocal microscopy.
  • Fig. 9 shows the results of detecting the gastric cancer cells of each group treated with different conditions for 12 hours by Rho protein activity assay.
  • Figure 10 is a graph showing the results of detecting the activity of matrix metalloproteinase-2 in each group of gastric cancer cells by gelatin matrix metalloproteinase activity assay.
  • Figure 11 shows the expression of phosphorylated SATA3, vimentin, transcription factor Snail and transcription factor Twist in each group of gastric cancer cells treated with statins at different times by Western blotting.
  • Figure 12 is a graph showing the expression of phosphorylated SATA3, vimentin, transcription factor Snail and transcription factor Twist in each of the gastric cancer cells treated with different conditions by Western blotting.
  • Figure 13 shows the statistical results of total mortality of gastric cancer between regular users and non-users of statins.
  • the invention discloses the use of a statin, in particular, because the statin has the ability to inhibit the growth, metastasis and invasion of gastric cancer cells, and can cause gastric cancer cells to apoptosis, therefore, by administering A pharmaceutical composition containing an effective amount of a statin to a gastric cancer patient can achieve the efficacy of manufacturing a gastric cancer.
  • statin compound is a drug currently used clinically to treat hyperlipidemia, mainly by inhibiting the activity of key enzymes in cholesterol synthesis in hepatocytes, reducing cholesterol production, and reducing the incidence of coronary heart disease. And mortality.
  • statins Compared with other hypolipidemic drugs, statins have fewer side effects. According to the statistics of existing studies, only 5% of patients have obvious side effects. Therefore, statins are considered to be highly safe.
  • Pharmaceutical composition There are many types of statins currently in clinical use, including lovastatin, simvastatin, fluvastatin, atorvastatin, and pravastatin (pravastatin). ), rosuvastatin, pitavastatin, and the like. The mechanism of action based on statins is similar, so that simvastatin is exemplified in the following examples, but this is not intended to limit the scope of the claims.
  • statins are initially used once a day, the dose is 2 ⁇ 80 mg, and the frequency of subsequent continuous use is once a day, the dose is 1 ⁇ 80 mg.
  • the dosage of different statins will vary, as shown in Table 1 below.
  • pharmaceutical composition is meant an effective amount of the desired compound or active ingredient to produce a particular effect, and at least one pharmaceutically acceptable carrier.
  • dosage form of the pharmaceutical composition varies depending on the manner in which the particular effect is to be caused, such as a lozenge, a powder, an injection, etc., and the carrier also follows the medicine.
  • the dosage form of the composition is obtained as a solid, semi-solid or liquid.
  • carriers include, but are not limited to, gelatin, emulsifiers, hydrocarbon mixtures, water, glycerin, physiological saline, buffered saline, lanolin, paraffin, beeswax, dimethicone, ethanol.
  • an effective amount is meant an amount of the active ingredient or compound to be produced in a pharmaceutical composition to produce the desired effect, usually expressed as a percentage by weight of the active ingredient or compound in the pharmaceutical composition. As is known to those of ordinary skill in the art to which the present invention pertains, the effective amount will be due to the administration of a particular effect. The way it is different. Generally, the active ingredient or compound will be present in the compositions in an amount of from about 1% to about 100%, preferably from about 30% to about 100% by weight of the composition.
  • Example 1 Effect of statins on cancer cell activity
  • Three gastric cancer cell lines were taken and cultured separately, and each of the gastric cancer cell lines was treated with simvastatin at concentrations of 0, 1.25, 2.5, 5, 10 and 20 ⁇ g/ml for 72 hours. .
  • the activity of each of the gastric cancer cell lines treated with different concentrations of simvastatin was analyzed by a cell activity staining assay (MTS assay), and the results are shown in Fig. 1.
  • MTS assay cell activity staining assay
  • the three gastric cancer cell lines were respectively divided into two groups, wherein the first group did not treat simvastatin; the second group was treated with simvastatin at a concentration of 20 ⁇ g/ml for 72 hours.
  • the cell viability of the first and second groups of each of the gastric cancer cell lines was analyzed by cell activity staining at 0, 24, 48 and 72 hours after simvastatin treatment, respectively, and the results are shown in Fig. 2.
  • each of the gastric cancer cell lines treated with different concentrations (0, 1.25, 2.5, 5, 10, and 20 ⁇ g/ml) of simvastatin was collected by flow cytometry (FCM) and TUNEL detection, respectively.
  • FCM flow cytometry
  • TUNEL detection TUNEL detection
  • statins such as simvastatin can actually reduce the activity of gastric cancer cells, and when the concentration of statin treatment is increased or the treatment time is increased, the activity of gastric cancer cells will also increase. low.
  • statin compounds such as simvastatin can induce apoptosis of gastric cancer cells, thereby reducing the activity of gastric cancer cells and inhibiting the growth of gastric cancer cells.
  • FIGS. 1 to 4 show that the statin compound of the present invention has an ability to inhibit the growth of gastric cancer cells and induce apoptosis of gastric cancer cells, and can be used as an active ingredient in a pharmaceutical compound for treating or slowing down gastric cancer and its symptoms.
  • Example 2 Effect of statins on apoptosis of cancer cells
  • the three gastric cancer cell lines: AGS, MKN45 and TSGH9201 were treated with simvastatin at a concentration of 20 ⁇ g/ml, respectively, and cultured at 0, 2, 6, 12 and 24 hours, respectively.
  • Protein-specific analysis was performed by Western blotting to observe proteins regulating gastric cancer cell apoptosis in each of the gastric cancer cell lines: MCL-1, BAX, Bcl-2, Bcl-xL, NOXA, PUMA, lytic protease -3 (cleaved caspase-3) and the performance of cleavage PARP (cleaved PARP),
  • ⁇ actin was a control group.
  • simvastatin can inhibit the expression of anti-apoptotic proteins: Bcl-2, Bcl-xL and Mcl-1L, and at the same time promote the promotion of apoptotic proteins: BAX, NOXA, PUMA and Mcl-1S. Markers that express and increase apoptosis: Apoptosis proteinase-3 and PARP.
  • the statin of the present invention can regulate the apoptosis of gastric cancer cells through the mitochondrial pathway in gastric cancer cells, and can make the gastric cancer cells go to apoptosis and achieve the effect of treating gastric cancer.
  • the three gastric cancer cell lines: AGS, MKN45 and TSGH9201 were divided into four groups, of which the first group was a blank group; the second group was treated with simvastatin at a concentration of 5 ⁇ g/ml; the third group was treated with 3 mM. Cells were treated with mevalonate; the fourth group was simultaneously treated with 5 ⁇ g/ml of simvastatin and 3 mM mevalonate.
  • Each of the gastric cancer cell lines treated under different conditions was cultured in a cell migration transwell medium for 12 hours to observe the metastasis of gastric cancer cells, and the results are shown in Fig. 6.
  • each of the gastric cancer cell lines treated under different conditions was cultured in a colloidal medium for 16 hours to observe gastric cancer cell erosion, and the results are shown in FIG.
  • fibroactin is one of the cytoskeletal components and an important physiological component for the transfer of cancer cells. Therefore, it is necessary to analyze the migration of cancer cells by observing fibronectin in the cells. . Therefore, after treating the first to fourth groups of each of the gastric cancer cell lines for 12 hours under the treatment conditions thereof, the cytoskeleton and the DAPI dye were labeled with rhodamine-labeled phalloidin. The nuclei were stained, fluorescent staining was performed, and the results of fluorescence staining were observed by confocal microscopy, as shown in Fig. 8. Among them, blue was the result of nuclear staining, and red was the result of fibronectin (F-actin) staining. .
  • Rho protein belongs to a small G protein family, has an activated state bound to GDP and an inactive state bound to GTP, and the excessive expression of Rho protein is closely related to tumor development and degree of malignancy, and thus By observing the expression of Rho protein in cells, it can be used to analyze the degree of development of tumor cells. Therefore, each group of gastric cancer cells treated under different conditions for 12 hours was examined by Rho protein activity assay, and the results are shown in FIG.
  • each of the gastric cancer cell lines of the first to fourth groups was treated under different conditions, cultured in a serum-free medium for 24 hours, and then detected by a gelatin matrix metalloproteinase assay (Gelatin zymogram assay).
  • a gelatin matrix metalloproteinase assay Gelatin zymogram assay.
  • the activities of matrix metalloproteinase-9 and matrix metalloproteinase-2 in gastric cancer cells, the activity of matrix metalloproteinase 2 in each group of gastric cancer cells is shown in Fig. 10.
  • matrix metalloproteinase-9 and matrix metalloproteinase 2 are considered to be associated with tumor metastasis, it is possible to detect the turnover of simvastatin on tumor cells by observing the activity of matrix metalloproteinase-9 and matrix metalloproteinase-2 in cells. influences.
  • statin of the present invention can inhibit the growth of gastric cancer cells and inhibit the invasion of other cells by inhibiting the growth of gastric cancer cells. Accordingly, the statins of the present invention have the efficacy of treating or ameliorating gastric cancer and related symptoms.
  • statins can negatively regulate the epithelial transition marker (EMT marker)
  • the three gastric cancer cell lines: AGS, MKN45 and TSGH9201 were treated with simvastatin at a concentration of 5 ⁇ g/ml, respectively, 0, 6, and 12. After 24 hours, the expression of phosphorylated SATA3, vimentin, transcription factor Snail, and transcription factor Twist in each of the cells treated with simvastatin for different times was measured by Western blotting, and the results are shown in FIG.
  • the three gastric cancer cell lines: AGS, MKN45, and TSGH9201 were respectively divided into four groups, and the treatment conditions of each of the groups were as described in Example 3, and the gastric cancer cells were treated according to the treatment conditions of each of the groups.
  • the expression of phosphorylated SATA3, vimentin, transcription factor Snail, and transcription factor Twist in each group of gastric cancer cells was determined by Western blotting, and the results are shown in FIG.
  • simvastatin can reduce the expression of transcription factors regulating the development of gastric cancer cells, and as the treatment time increases, the expression of transcription factors also decreases. From the results of FIG. 12, it was found that the expression factors of the gastric cancer cells related to the development of gastric cancer in the first group, the third group, and the fourth group did not decrease. In contrast, the transcription factors associated with the development of gastric cancer in the second group of gastric cancer cells were significantly decreased.
  • statin compound disclosed in the present invention can inhibit the continued development of gastric cancer cells, and can achieve the efficacy of treating or improving gastric cancer and related diseases.
  • the 25010 patients were divided into three groups according to the frequency of their administration of statins. Among them, there were 22867 patients in the non-use group; 1176 patients in the regular use group; and 967 patients in the use group. After using the statin tendency and continuing to administer the drug for 3 months, the regular use group and the non-frequent use group were distributed in a ratio of 1:4, and the non-use group was divided into 4484 patients, and the frequently used group had 1121 patients, among which, Patient data are shown in Table 2 below.
  • the pharmaceutical composition containing the statin compound of the present invention can indeed treat or improve gastric cancer and/or its related symptoms, and the present invention is compared with the prior art.
  • the disclosed pharmaceutical composition can not only reduce the production cost, but also provide better prognosis survival rate and survival years for gastric cancer patients.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une utilisation d'un composé de statine pour la préparation de compositions pharmaceutiques destinées à traiter des cancers de l'estomac. Le composé peut induire l'apoptose des cellules de cancer de l'estomac, inhiber la croissance et la métastase des cellules de cancer de l'estomac et réguler négativement des facteurs de transcription liés au développement d'un cancer de l'estomac.<sb />
PCT/CN2015/084434 2015-07-20 2015-07-20 Utilisation de composé de statine pour le traitement de cancers de l'estomac Ceased WO2017011973A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/084434 WO2017011973A1 (fr) 2015-07-20 2015-07-20 Utilisation de composé de statine pour le traitement de cancers de l'estomac

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2015/084434 WO2017011973A1 (fr) 2015-07-20 2015-07-20 Utilisation de composé de statine pour le traitement de cancers de l'estomac

Publications (1)

Publication Number Publication Date
WO2017011973A1 true WO2017011973A1 (fr) 2017-01-26

Family

ID=57833587

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/084434 Ceased WO2017011973A1 (fr) 2015-07-20 2015-07-20 Utilisation de composé de statine pour le traitement de cancers de l'estomac

Country Status (1)

Country Link
WO (1) WO2017011973A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364076A (zh) * 2022-07-11 2022-11-22 中国人民解放军总医院第五医学中心 二萜类化合物db-022133在制备治疗胃癌药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FENG, XINGBO;: "Study on the inhibitory effect of lovastatin on the growth of xenografted gastric cancer line MKN45 in nude mice", MEDICINE & PUBLIC HEALTH, CHINA MASTER'S THESES FULL-TEXT DATABASE, 15 January 2013 (2013-01-15), pages E072 - 349, ISSN: 1674-0246 *
ZHENG, ZHIXIN: "Apoptotic activity of simvastatin against gastric cancer cell and its effect on survivin protein", CHINA JOURNAL OF MODERN MEDICINE, vol. 24, no. 11, 30 April 2014 (2014-04-30), pages 51 - 54, ISSN: 1005-8982 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115364076A (zh) * 2022-07-11 2022-11-22 中国人民解放军总医院第五医学中心 二萜类化合物db-022133在制备治疗胃癌药物中的应用
CN115364076B (zh) * 2022-07-11 2024-04-16 中国人民解放军总医院第五医学中心 二萜类化合物db-022133在制备治疗胃癌药物中的应用

Similar Documents

Publication Publication Date Title
CN102083430B (zh) 大麻类化合物组合物在制备治疗脑部肿瘤药物中的用途
Balcerzak et al. A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study
US6187315B1 (en) Compositions and methods of treating cancer with tannin complexes
JPWO2009028605A1 (ja) 抗がん剤による末梢神経障害の予防又は軽減剤
EP3197445B1 (fr) Proline ou dérivés de proline pour le traitement de la démence
WO2018113027A1 (fr) Application du bilobalide comme activateur dans la préparation de médicaments pour la prévention de maladies de type lésions de nerfs crâniens
CN114209683A (zh) 壬二酸在制备治疗炎症性肠病药物中的应用
US11524021B2 (en) Use of ginsenoside M1 for manufacturing medicament for treating oral cancer
CN103315981A (zh) 一种联苯二酚和/或其衍生物在制备抑制癌细胞转移药物中的应用
TWI607751B (zh) Statin compounds for the treatment of gastric cancer
WO2017011973A1 (fr) Utilisation de composé de statine pour le traitement de cancers de l&#39;estomac
CN116492320B (zh) 大果桉醛i在制备肿瘤免疫治疗增效剂中的应用
US20180318235A1 (en) Zeaxanthin for Tumor Treatment
JP2014221752A (ja) ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬
CN111671909A (zh) 他汀类药物联合ror激动剂在治疗结直肠癌方面的应用
CN116492342B (zh) 氯喹或羟氯喹在制备治疗尼洛替尼肾脏毒副作用药物中的应用
CN113527151B (zh) 一种抗肿瘤小分子化合物的作用机制及应用
WO2021000926A1 (fr) Utilisation de ginsénoside m1 pour le traitement du cancer
CN110269939A (zh) 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
CN119837851A (zh) 金丝桃素在制备治疗钙化性主动脉瓣疾病产品中的应用
TW202415366A (zh) 異硫氰酸酯結構修飾化合物於預防或治療肝臟疾病之用途
US20130079416A1 (en) Homeopathic medicament comprising phenacetin for the treatment of cancer
CN119302935A (zh) 苄索氯胺作为stat3抑制剂在制备治疗头颈部肿瘤药物的应用
CN116549467A (zh) 人参皂苷Rf在制备PD-1抑制剂抗肿瘤药物的增强剂中的应用
CN116549504A (zh) 一种用于治疗黑色素瘤的药物组合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15898529

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15898529

Country of ref document: EP

Kind code of ref document: A1